Development and optimization of CRISPR-based epigenetic editing to modulate gene expression in cancer cell lines for therapeutic applications

Project Abstract

CRISPR-based epigenetic editing offers a precise modality to alter gene expression without changing the underlying DNA sequence, presenting a transformative approach for targeting oncogenic or tumor-suppressive pathways in cancer cell lines. This study presents a systematic optimization of CRISPR-dCas9 effector fusions, integrating DNA methyltransferase and demethylase activities, histone acetyltransferase, and repressive complexes to achieve locus-specific modulation of gene expression with minimized off-target effects. We engineered multiplexed guide RNA (gRNA) libraries targeting key regulatory regions of oncogenes and tumor suppressor genes across a panel of human cancer cell lines representing diverse tissue origins and mutational landscapes. Through iterative cycles of design-build-test, we evaluated transcriptional outcomes using quantitative RT-PCR, RNA-seq, and single-cell transcriptomics to capture both population-wide and clonal heterogeneity in response. Epigenetic state changes were profiled by bisulfite sequencing, ChIP-seq for histone marks (H3K27ac, H3K9me3, H3K4me3), and ATAC-seq to assess chromatin accessibility, enabling mechanistic correlations between epigenetic remodeling and downstream gene expression. Functional consequences were assessed via proliferation assays, cell-cycle analyses, apoptosis markers, and colony formation assays, complemented by in vivo validation in xenograft models to evaluate tumor growth modulation and potential off-target oncogenic risks. A key focus was optimizing the delivery modality and expression kinetics of epigenetic editors to maximize on-target efficacy while preserving cellular homeostasis, achieved through inducible dCas9 constructs and non-viral delivery platforms, as well as temporal control of effector activity to mitigate unintended epigenomic perturbations. Our data demonstrate that targeted deposition or removal of activating and repressive histone marks, in combination with methylation editors, can selectively upregulate tumor suppressor genes or silence oncogenic drivers, resulting in restored apoptotic responses and reduced proliferative capacity in resistant cancer models. We also delineate a framework for evaluating specificity by integrating high-fidelity Cas9 variants, truncated gRNAs, and comprehensive off-target profiling, including GUIDE-seq and whole-genome bisulfite sequencing, to quantify unintended epigenetic alterations. Computational modeling coupled with machine learning analyses identified predictive features of responsive loci, including chromatin state, sequence context, and three-dimensional genome architecture, enabling prioritization of therapeutic targets. The study further assesses potential combinatorial strategies by pairing epigenetic editing with conventional chemotherapeutics or targeted inhibitors to overcome resistance mechanisms and enhance synergy. Collectively, these findings advance the feasibility of CRISPR-based epigenetic therapies by providing a robust toolkit for precise, durable, and safe modulation of gene expression in cancer, with implications for personalized medicine where patient-specific epigenomic landscapes inform targeted interventions. This work sets the stage for translational development, including regulatory considerations, scalability, and long-term safety assessments essential for clinical deployment.

Project Overview

What This Project Is About

---

A straightforward, beginner-friendly explanation of the study. It looks at how CRISPR can be used to adjust epigenetic marks—chemical changes on DNA or its associated proteins—to turn genes on or off in cancer cells without changing the DNA sequence itself. The goal is to see if these edits can reliably influence cancer-related genes and be a potential therapy option.

---

---

The Problem It Addresses

---

Cancer is driven by abnormal gene activity. Traditional treatments can affect healthy cells and have side effects. This project focuses on a gentler approach that targets gene regulation rather than altering the DNA, hoping for precision in stopping cancer growth with fewer side effects.

---

---

Objectives of the Project

---

1. Explain the basic idea of epigenetic editing and why CRISPR is useful here.
2. Identify key cancer genes suitable for epigenetic modulation.
3. Demonstrate a simple CRISPR-based method to change gene activity in cell lines.
4. Assess how well these edits control target gene expression.
5. Evaluate potential off-target effects and safety considerations.

---

---

What You Will Do Step by Step

---

1. Review introductory literature on CRISPR and epigenetics.
2. Design a basic experimental plan for epigenetic modification in cancer cells.
3. Set up cell culture and apply a simple CRISPR-based editing approach.
4. Measure changes in gene activity using accessible assays (e.g., expression levels).
5. Analyze data to see if the edits produce the intended effect.
6. Discuss potential limitations and improvements for future work.

---

---

Expected Outcome

Typically, clear evidence that targeted epigenetic edits can modify the expression of chosen cancer-related genes in cell lines, with a rational discussion of how this could inform safer, more precise cancer therapies.